AstraZeneca has agreed to sell part of its antibiotics business to Pfizer for up to $1.575 billion plus royalties, giving Pfizer the right to sell three approved drugs and two now in clinical trials in most markets outside the U.S.
WSJ.com: US Business, Wall Street Journal: Business
Tue, 08/23/2016 - 11:47pm
AstraZeneca has agreed to sell part of its antibiotics business to Pfizer for up to $1.575 billion plus royalties, giving Pfizer the right to sell three approved drugs and two now in clinical trials in most markets outside the U.S.